Semaglutide: Alkem launches Rs 350 syringes in India

Launch announcement and what changed

Alkem Laboratories has launched semaglutide in single-shot, pre-filled syringes in India, with a starting price of Rs 350. The Mumbai-based drugmaker said it is the first company in the country to offer semaglutide in this ready-to-use, single-use syringe format. The product is being rolled out in phases, with the syringe launch following earlier introductions of pen-based formats. The company positioned the new format as a way to improve convenience while lowering entry barriers to treatment through affordable pricing. The launch comes at a time when several companies are expanding offerings in the broader GLP-1 category for diabetes and weight management.

Pricing and the patient access angle

Alkem set the starting price of the single-shot pre-filled syringe at Rs 350. The company said the format is designed to alter the pricing structure and accessibility of semaglutide treatments for patients in India. It described the product as ready-to-use, with the single-shot approach aimed at convenience. The stated intent is to make treatment easier to start for patients who may be sensitive to upfront costs. The pricing move also highlights how packaging and delivery formats are being used to compete alongside the active ingredient itself.

Regulatory status and approved use

Alkem said it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes across multiple dosage strengths. The therapy is indicated for the management of Type 2 diabetes mellitus and obesity. The company said semaglutide is to be used as an adjunct to diet and exercise. This regulatory clearance is central to Alkem’s India rollout, because it enables commercial distribution of the product in the pre-filled syringe format.

Rollout plan: pens first, syringes next

The company’s semaglutide rollout in India has been structured in phases. In March 2026, Alkem launched semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market. In June 2026, it followed with the single-shot pre-filled syringes. This sequencing indicates Alkem is expanding delivery options rather than relying on one presentation. It also signals a push to cover different patient preferences and prescribing practices.

Brands, dosing cadence, and earlier pen pricing

Alkem’s semaglutide injection has been reported under the brand names “Semasize,” “Obesema,” and “Hepaglide.” The therapy is administered once weekly via subcutaneous injection. One reported configuration is a pre-filled disposable injection pen containing four doses for a month, priced at Rs 1,800, which works out to Rs 450 per week. The newly launched single-shot pre-filled syringe starts at Rs 350, creating another entry price point within the same therapeutic category. These price references highlight how cost can vary by format and pack design.

Vials also on the roadmap

Beyond pens and the newly launched single-shot syringes, Alkem has also received regulatory approval related to semaglutide vials. The company said vials are expected to be launched soon. This adds a third delivery option that could appeal to different segments of the market, including settings where conventional vial usage is common. The mix of pens, syringes, and vials suggests a broad commercial approach to meet varied patient and provider needs.

Competitive context in India’s semaglutide market

The launch adds to intensifying competition in India’s market for diabetes and weight-management medicines. Alkem has said it is the first to bring semaglutide in a pre-filled syringe, while rivals continue to market their formulations in conventional vials and pens. The competitive landscape has also been linked in reporting to a steep decline in API prices and rising competition. Separately, domestic peers such as Torrent Pharma and Dr Reddy’s have introduced non-infringing tablets, and Lupin, Sun Pharma, and others have been expected to follow suit. Natco Pharma has also launched a generic semaglutide injection in India, underlining a widening field of participants.

Patent-expiry backdrop and why timing matters

Alkem’s entry into India’s GLP-1 space has been linked to the March 21, 2026 patent expiry in India for Novo Nordisk’s Ozempic and Wegovy, as cited in reporting around the launches. That timing has helped accelerate product rollouts by Indian manufacturers. It has also increased focus on how companies differentiate through formats, strengths, and pricing. In that context, Alkem’s single-shot syringe format stands out as a packaging-led differentiation in a market where more players are moving into semaglutide.

Key facts at a glance

Market impact: pricing, formats, and competition

The most immediate market implication is pricing visibility in a category where delivery format can influence affordability and convenience. Alkem’s starting price of Rs 350 for a single-shot pre-filled syringe sits alongside its reported monthly pen price of Rs 1,800 for four doses, or Rs 450 per week. Competitive references in reporting also note that other companies, such as Sun Pharma, offer treatments from Rs 750 to Rs 2,000 monthly. With more companies introducing semaglutide-linked options, the market is seeing more format variety, including pens, vials, and now single-use syringes. The DCGI approval across multiple dosage strengths supports broader prescribing flexibility within the approved indications.

Analysis: why the single-shot syringe format stands out

Alkem’s claim of being the first in India to market semaglutide in single-shot pre-filled syringes matters because it creates a differentiated option in administration and purchase size. A ready-to-use, single-shot product can lower the threshold for initiating therapy, especially where patients may prefer smaller upfront spends or simpler handling. The phased rollout also shows an intent to compete across segments rather than through one flagship presentation. At the same time, competitive pressure is clearly rising, with multiple domestic players active and more expected, making pricing and format strategy a central lever for market share.

Conclusion

Alkem’s launch of semaglutide single-shot pre-filled syringes at a starting price of Rs 350, backed by DCGI approval for multiple dose strengths, expands how the drug can be accessed in India. The rollout builds on Alkem’s March 2026 pen launches and comes with plans to introduce vials after securing regulatory clearance. As more companies enter the semaglutide and broader GLP-1 space, delivery formats and transparent price points are likely to remain a key part of how products are positioned in the market.